AVROBIO, Inc. (AVRO) gained significantly in the pre-market after the company announced Phase ½ clinical trial results for cystinosis. AVRO values at $1.80, gaining more than 2.27% from the previously closed value. The stock closed at around $1.76 at the end of the previous trading session. The stock traded volume in the last trading session was around 984.5K shares.
AVROBIO announces Phase 1/2 Clinical Trial Results for Cystinosis
AVROBIO released Interim results from a Phase 1/2 clinical trial of AVR-RD-04 today. The collaborator is supporting an innovative gene treatment for cystinosis. The news was made at the 18th Annual WORLDSymposium in San Diego.
The first three patients are still off oral cysteamine 12–26 months after receiving AVR-RD-04. These patients exhibited steady vector copy number (VCN) readings, indicating engraftment. A fourth patient was injected in November 2021. The medical product has had no known side reactions in the four patients who have received it.
AVRO CEO’s remarks about the trial results
According to AVROBIO CEO Geoff MacKay, the significant unmet need of cystinosis patients drives new treatment development. Achieving cures requires kidney transplantation with chronic immunosuppression and substantially shorter lifetimes. These interim results are ready to start their AVROBIO-sponsored cystinosis clinical trial in 2023.
AVRO trial set for 2023
The AVROBIO-sponsored trial will hopefully roll out in the United States in 2023. The next target market is Europe and the United Kingdom. Pre-renal transplant and post-renal transplant populations will be the focus of AVROBIO’s current strategy. The company decided after the feedback provided in a report by the FDA today.
Conclusion
The drug formulation has not caused any side effects in the four patients treated so far. The company seems confident about the drug and expects to launch it for public use in the US and other European markets. It will increase the company’s revenue and thus increase its value.
